| Literature DB >> 36038663 |
Ying Zhan1, Wei Qiao1, Bolong Yi2,3,4, Xinyu Yang2,3,4, Miaomiao Li2,3,4, Lu Sun1, Lian Ji5, Peng Su5, Xin Wang1, Furong Zhang2,3,4, Rui Zhang2,3,4, Mingjun Gao2,3,4, Wujun Zhao2,3,4, Yichen Song6,7,8.
Abstract
Dysregulation of pseudogenes, enhancement of fatty acid synthesis and formation of immunosuppressive microenvironment are important factors that promote the malignant progression of glioma. It is of great significance to search for the molecular mechanism of interaction between the three and then perform targeted interference for improving the treatment of glioma. In this study, we found that pseudogene transmembrane protein 198B (TMEM198B) was highly expressed in glioma tissues and cell lines, and it could promote malignant progression of glioma by regulating lipid metabolism reprogramming and remodeling immune microenvironment. Applying the experimental methods of gene interference, lipidomics and immunology, we further confirmed that TMEM198B promoted PLAG1 like zinc finger 2 (PLAGL2) expression by mediating tri-methylation of histone H3 on lysine 4 (H3K4me3) of PLAGL2 through binding to SET domain containing 1B (SETD1B). Increased PLAGL2 could transcriptional activate ATP citrate lyase (ACLY) and ELOVL fatty acid elongase 6 (ELOVL6) expression, and then influenced the biological behaviors of glioma cells via enhancing the de novo lipogenesis and fatty acid acyl chain elongation. At the same time, TMEM198B promoted macrophages lipid accumulation and intensification of fatty acid oxidation (FAO) through glioma-derived exosomes (GDEs), further induced macrophages to M2 polarization, which subsequently facilitated immune escape of glioma cells. In conclusion, our present study clarifies that the TMEM198B/PLAGL2/ACLY/ELOVL6 pathway conducts crucial regulatory effects on the malignant progression of glioma, which provides novel targets and new ideas for molecular targeted therapy and immunotherapy of glioma.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36038663 DOI: 10.1038/s41388-022-02445-0
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 8.756